BNP Paribas Asset Management
TGTX icon

BNP Paribas Asset Management’s TG Therapeutics TGTX Stock Holding History

BNP Paribas Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Sell
2,156
-164
-7% -$6.71K ﹤0.01% 1512
2026
Q1 		$77.1K Buy
2,320
+419
+22% +$12.5K ﹤0.01% 1591
2025
Q4 		$57K Buy
1,901
+567
+43% +$18.5K ﹤0.01% 1626
2025
Q3 		$48K Sell
1,334
-23
-2% -$758 ﹤0.01% 1077
2025
Q2 		$49K Buy
+1,357
New +$50.5K ﹤0.01% 1156

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

BNP Paribas Asset Management's TGTX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its TG Therapeutics (TGTX) stake by 7.1% in Q2 2026, selling an estimated $6.71K and leaving 2,156 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #1512.

BNP Paribas Asset Management first reported a position in TGTX in Q2 2025 and has held it in 5 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • BNP Paribas Asset Management held 2,156 shares of TG Therapeutics worth $118K as of Q2 2026.
  • BNP Paribas Asset Management sold 164 TG Therapeutics shares in Q2 2026, an estimated $6.71K.
  • TG Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1512 holding.
  • BNP Paribas Asset Management first reported a position in TG Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.